Revolution Medicines, Inc.
General ticker "RVMD" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $15.0B (TTM average)
Revolution Medicines, Inc. follows the US Stock Market performance with the rate: 55.9%.
Estimated limits based on current volatility of 2.0%: low 177.65$, high 184.89$
Factors to consider:
- Total employees count: 883 (+65.4%) as of 2025
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Limited operating history, Need for additional capital, Product development failure, Regulatory and compliance, Inability to commercialize
- Current price 77.6% above estimated high
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [45.98$, 104.81$]
- 2026-12-31 to 2027-12-31 estimated range: [30.03$, 73.54$]
Financial Metrics affecting the RVMD estimates:
- Negative: with PPE of -13.4 at the end of fiscal year the price was very high
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Positive: Investing cash flow per share per price, % of 0.78 > -0.60
- Positive: Inventory ratio change, % of 0 <= 0
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Industry operating cash flow (median)
Short-term RVMD quotes
Long-term RVMD plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $11.58MM | $0.00MM | $0.00MM |
| Operating Expenses | $498.76MM | $689.52MM | $1,182.37MM |
| Operating Income | $-487.19MM | $-689.52MM | $-1,182.37MM |
| Non-Operating Income | $47.29MM | $88.68MM | $51.07MM |
| Interest Expense | $0.00MM | $0.00MM | $24.23MM |
| R&D Expense | $423.14MM | $592.23MM | $987.33MM |
| Income(Loss) | $-439.89MM | $-600.85MM | $-1,131.30MM |
| Taxes | $-3.52MM | $-0.75MM | $0.00MM |
| Net Income(Loss)* | $-436.37MM | $-600.09MM | $-1,131.30MM |
| Stockholders Equity | $1,826.19MM | $2,265.20MM | $1,631.30MM |
| Assets | $2,061.70MM | $2,558.30MM | $2,354.51MM |
| Operating Cash Flow | $-350.57MM | $-557.44MM | $-897.74MM |
| Capital expenditure | $7.73MM | $10.31MM | $15.99MM |
| Investing Cash Flow | $-342.60MM | $-554.39MM | $118.06MM |
| Financing Cash Flow | $1,229.20MM | $959.41MM | $621.52MM |
| Earnings Per Share** | $-3.86 | $-3.58 | $-5.95 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.